JP2020527581A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527581A5 JP2020527581A5 JP2020502514A JP2020502514A JP2020527581A5 JP 2020527581 A5 JP2020527581 A5 JP 2020527581A5 JP 2020502514 A JP2020502514 A JP 2020502514A JP 2020502514 A JP2020502514 A JP 2020502514A JP 2020527581 A5 JP2020527581 A5 JP 2020527581A5
- Authority
- JP
- Japan
- Prior art keywords
- positions
- region
- cancer
- variant
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762477661P | 2017-03-28 | 2017-03-28 | |
| US62/477,661 | 2017-03-28 | ||
| PCT/US2018/024872 WO2018183520A1 (en) | 2017-03-28 | 2018-03-28 | Therapeutic agents and methods for enhancing immune responses in tumor microenvironment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527581A JP2020527581A (ja) | 2020-09-10 |
| JP2020527581A5 true JP2020527581A5 (enExample) | 2021-05-06 |
| JP7395463B2 JP7395463B2 (ja) | 2023-12-11 |
Family
ID=63677056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020502514A Active JP7395463B2 (ja) | 2017-03-28 | 2018-03-28 | 腫瘍微小環境における免疫応答を増強するための治療剤および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12024560B2 (enExample) |
| EP (1) | EP3601333A4 (enExample) |
| JP (1) | JP7395463B2 (enExample) |
| KR (1) | KR20200006526A (enExample) |
| CN (7) | CN113603780B (enExample) |
| AU (1) | AU2018244574A1 (enExample) |
| CA (1) | CA3058185A1 (enExample) |
| WO (1) | WO2018183520A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7682102B2 (ja) * | 2019-05-10 | 2025-05-23 | リビジェン バイオファーマ ホールディングス リミテッド | ヒト化抗ｃｄ１３７抗体およびその使用 |
| EP4071167A4 (en) * | 2019-12-03 | 2024-03-06 | Shanghai Jiao Tong University School of Medicine | ANTIBODIES FC REGION WITH INCREASED FCGRIB AFFINITY |
| TWI869528B (zh) | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| CN114106174A (zh) * | 2020-08-27 | 2022-03-01 | 苏州景涞医疗科技有限公司 | 低毒性抗ox40抗体、其药物组合物及应用 |
| JP2024500945A (ja) * | 2020-12-23 | 2024-01-10 | マクファーレン バーネット インスティテュート フォー メディカル リサーチ アンド パブリック ヘルス リミテッド | ＦｃガンマＲＩＩｂに対する親和性を有する修飾免疫グロブリン及びその使用方法 |
| CA3173944A1 (en) | 2021-01-13 | 2022-07-21 | Visterra, Inc. | Humanized complement 5a receptor 1 antibodies and methods of use thereof |
| CN117295760A (zh) * | 2021-05-07 | 2023-12-26 | 信达生物制药(苏州)有限公司 | 与Fc受体结合改变的Fc突变体 |
| CN121843714A (zh) | 2023-08-11 | 2026-04-10 | 派拉冈医疗公司 | Tl1a结合抗体及使用方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040132101A1 (en) * | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| WO2006085967A2 (en) * | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| CN101098890B (zh) * | 2004-11-12 | 2012-07-18 | 赞科股份有限公司 | 对FcRn的结合被改变的Fc变体 |
| WO2006105338A2 (en) | 2005-03-31 | 2006-10-05 | Xencor, Inc. | Fc VARIANTS WITH OPTIMIZED PROPERTIES |
| WO2008092117A2 (en) | 2007-01-25 | 2008-07-31 | Xencor, Inc. | Immunoglobulins with modifications in the fcr binding region |
| EP2144931A2 (en) | 2007-04-04 | 2010-01-20 | The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services | Monoclonal antibodies against dengue and other viruses with deletion in fc region |
| JP2010526868A (ja) * | 2007-05-14 | 2010-08-05 | ノビミューン エスアー | 改変されたエフェクター機能を有するＦｃ受容体結合ポリペプチド |
| EP2176298B1 (en) * | 2007-05-30 | 2017-11-15 | Xencor, Inc. | Methods and compositions for inhibiting cd32b expressing cells |
| ES3006441T3 (en) * | 2007-09-14 | 2025-03-18 | Amgen Inc | Homogeneous antibody populations |
| KR101680906B1 (ko) * | 2007-09-26 | 2016-11-30 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| JP2013528357A (ja) * | 2010-03-29 | 2013-07-11 | ザイムワークス，インコーポレイテッド | 強化又は抑制されたエフェクター機能を有する抗体 |
| WO2012087928A2 (en) * | 2010-12-20 | 2012-06-28 | The Rockefeller University | Modulating agonistic tnfr antibodies |
| ES2623912T3 (es) * | 2010-12-23 | 2017-07-12 | Janssen Biotech, Inc. | Mutantes FC de anticuerpo activo resistente a proteasa |
| MX2018012383A (es) * | 2011-03-30 | 2023-03-07 | Chugai Pharmaceutical Co Ltd | Método para alterar la retención en plasma e inmunogenicidad de la molécula de union al antígeno. |
| UA117901C2 (uk) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| HUE033245T2 (hu) | 2011-12-19 | 2017-11-28 | Synimmune Gmbh | Bispecifikus ellenanyag molekula |
| SG10201709559PA (en) * | 2012-08-24 | 2017-12-28 | Chugai Pharmaceutical Co Ltd | Fcγriib-specific fc region variant |
| GB201216649D0 (en) * | 2012-09-18 | 2012-10-31 | Univ Birmingham | Agents and methods |
| CA2891764A1 (en) * | 2012-11-19 | 2014-05-22 | Baliopharm Ag | Recombinant bispecific antibody binding to cd20 and cd95 |
| HK1220470A1 (zh) | 2013-03-15 | 2017-05-05 | Abbvie Biotechnology Ltd. | 抗cd25抗体及其用途 |
| US20140377253A1 (en) | 2013-03-15 | 2014-12-25 | Abbvie Biotherapeutics Inc. | Fc variants |
| SG10201708048XA (en) * | 2013-03-18 | 2017-10-30 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
| CN105246914B (zh) * | 2013-04-02 | 2021-08-27 | 中外制药株式会社 | Fc区变体 |
| WO2014177459A2 (en) * | 2013-04-29 | 2014-11-06 | F. Hoffmann-La Roche Ag | Fc-receptor binding modified asymmetric antibodies and methods of use |
| GB201308658D0 (en) * | 2013-05-14 | 2013-06-26 | Isis Innovation | Antibodies |
| EP3041863A4 (en) * | 2013-09-05 | 2017-08-16 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| CA2939201A1 (en) * | 2014-03-05 | 2015-09-11 | Ucb Biopharma Sprl | Multimeric fc proteins |
| MX2016010951A (es) | 2014-03-05 | 2016-11-29 | Ucb Biopharma Sprl | Proteinas de fc multimericas. |
| EP2990416B1 (en) * | 2014-08-29 | 2018-06-20 | GEMoaB Monoclonals GmbH | Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders |
| AU2015349878A1 (en) * | 2014-11-21 | 2017-05-25 | Bristol-Myers Squibb Company | Antibodies against CD73 and uses thereof |
| AU2016276981B2 (en) * | 2015-06-12 | 2022-10-06 | Alector Llc | Anti-CD33 antibodies and methods of use thereof |
| KR20180054639A (ko) * | 2015-08-28 | 2018-05-24 | 알렉터 엘엘씨 | 항-siglec-7 항체 및 이의 사용 방법 |
| BR112018074453A2 (pt) | 2016-05-27 | 2019-03-19 | Abbvie Biotherapeutics Inc. | proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral |
| CN112996818B (zh) * | 2018-09-28 | 2022-06-21 | 礼进生物医药科技（上海）有限公司 | 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途 |
| JP7682102B2 (ja) * | 2019-05-10 | 2025-05-23 | リビジェン バイオファーマ ホールディングス リミテッド | ヒト化抗ｃｄ１３７抗体およびその使用 |
-
2018
- 2018-03-28 CN CN202110948281.3A patent/CN113603780B/zh active Active
- 2018-03-28 CN CN202110948290.2A patent/CN113603781B/zh active Active
- 2018-03-28 EP EP18776989.8A patent/EP3601333A4/en not_active Withdrawn
- 2018-03-28 JP JP2020502514A patent/JP7395463B2/ja active Active
- 2018-03-28 CN CN202110603621.9A patent/CN113201071A/zh active Pending
- 2018-03-28 AU AU2018244574A patent/AU2018244574A1/en not_active Abandoned
- 2018-03-28 CN CN202110609488.8A patent/CN113336849A/zh active Pending
- 2018-03-28 KR KR1020197031630A patent/KR20200006526A/ko not_active Ceased
- 2018-03-28 CA CA3058185A patent/CA3058185A1/en active Pending
- 2018-03-28 CN CN202110948301.7A patent/CN113480655B/zh active Active
- 2018-03-28 CN CN201880026106.5A patent/CN110546162B/zh active Active
- 2018-03-28 WO PCT/US2018/024872 patent/WO2018183520A1/en not_active Ceased
- 2018-03-28 US US16/498,784 patent/US12024560B2/en active Active
- 2018-03-28 CN CN202110948283.2A patent/CN113480654B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020527581A5 (enExample) | ||
| US10556959B2 (en) | Anti-CD39 antibodies and uses thereof | |
| US10308721B2 (en) | Anti-DLL3 antibodies and drug conjugates for use in melanoma | |
| CN114409786B (zh) | 结合ctla-4的抗体及其用途 | |
| JP2023509196A5 (enExample) | ||
| JP2007536932A5 (enExample) | ||
| ES2573642T3 (es) | Anticuerpos anti-FLT3 y métodos de usar los mismos | |
| JP2013529059A5 (enExample) | ||
| JP2019532619A5 (enExample) | ||
| JP2018506277A5 (enExample) | ||
| WO2006089133A8 (en) | Anti-cd19 antibodies and uses in oncology | |
| AU2014348552A1 (en) | Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof | |
| WO2008047242A3 (en) | Novel anti-cd38 antibodies for the treatment of cancer | |
| AU2014262566A1 (en) | Bispecific HER2 and HER3 antigen binding constructs | |
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| JP2021522303A5 (enExample) | ||
| EP3850009A1 (en) | B7-h7-binding agents and methods of use thereof | |
| AU2015308854A1 (en) | Combination therapy for treatment of cancer | |
| JP2017515473A5 (enExample) | ||
| SA519402119B1 (ar) | أجسام مضادة لعامل مثبط لابيضاض الدم واستخدامها (lif) | |
| CN111247173A (zh) | 抗msln抗体及包含其的用于癌症治疗的药物组合物 | |
| CN113631571B (zh) | 抗骨膜蛋白抗体及其用途 | |
| CA2633080A1 (en) | Method for preparing antibodies selective for activating fc receptors | |
| US20230265208A1 (en) | Antibodies against the muc1-c/extracellular domain (muc1-c/ecd) | |
| JP2023539453A5 (enExample) |